Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK

Academic Article

Abstract

  • We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads. © 2012 Thomas Land Publishers, Inc.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Dejesus E; Rockstroh J; Lennox J; Saag M; Lazzarin A; Zhao J; Wan H; Rodgers A; Walker M; Miller M
  • Start Page

  • 228
  • End Page

  • 232
  • Volume

  • 13
  • Issue

  • 4